“If the compound can be made, Symeres will undoubtedly find out a good way to make it.” Dooyoung Jung, CEO of Pinotbio.

An in-depth interview with Doo Young Jung, the founder and CEO of our client Pinotbio in South Korea, focused on the challenge of cancer resistance/relapse

Read more

New video of our Solid-State Center of Excellence

In this new video our colleagues Gabriella Pizutti, Chantalle van Berkel, and Eva Verhofstad, will give you an exciting lab tour through the Symeres Solid-State Centre of Excellence, located at the Symeres site in Weert, the Netherlands. You will learn more about PhysChem Properties, Solid Form Screening, Crystallization, Crystal Habit, Pre-formulation, and Formulation. Feel free to contact us via the contact form on this website if you would like to learn more about our Solid-State capabilities.

Read more

New scientific services from Symeres

We’re proud to announce that our brand new CMC facility at the Exemplify site of Symeres in New Jersey has been successfully completed. GMP drug product R&D facilities that will allow it to provide end-to-end services ranging from GMP and non-GMP drug product development to phase 1 and 2 clinical supplies of various oral, parenteral, and topical formulation dosage forms.

Read more

Interview with the new Managing Director of Symeres Groningen

On October 2, Dr Melloney Dröge started in her new role as Managing Director for the Groningen site.

Read more

Chiral Chemistry: in the DNA of Symeres

Over 50% of current drugs in development are chiral. At Symeres we apply a suite of state-of-the-art technologies to obtain the desired chiral compound in high enantiomeric purity. For decades, Symeres has been supporting the global pharma and biotech industry with the synthesis and delivery of chiral compounds, both through synthesis and purification strategies.

Read more

Symeres Weert receives new GMP certificate

This week, our facility in Weert NL received a new certificate of GMP compliance from the Dutch authorities.

Read more